← Back to Search

Interleukin-2 for HIV Infection

Phase 1
Waitlist Available
Research Sponsored by Chiron Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have been on stable anti-HIV therapy for 4 months, taking at least 2 drugs, 1 of which must be a protease inhibitor or a nonnucleoside drug (NNRTI)
Patients must be at least 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial will test if L2-7001, a type of interleukin-2, is safe and effective to give to HIV-positive patients in addition to their anti-HIV therapy.

Who is the study for?
This trial is for HIV-positive adults with a CD4 count of 300-500 cells/mm3, viral load under 10,000 copies/ml, on stable anti-HIV therapy for 4 months including protease inhibitors or NNRTIs. Participants must not have AIDS-defining illnesses, severe medical conditions like uncontrolled diabetes or thyroid issues, history of autoimmune diseases or cancer requiring chemotherapy. They cannot be pregnant/breastfeeding and must agree to use condoms.Check my eligibility
What is being tested?
The study tests the safety and effectiveness of L2-7001 (Interleukin-2) combined with current anti-HIV medications in boosting the immune system of HIV-positive patients. Interleukin-2 is naturally made by white blood cells and may help fight infection better when given as treatment.See study design
What are the potential side effects?
Potential side effects include reactions related to immune system activation such as fever, fatigue, injection site reactions since IL-2 boosts white blood cell activity. There might also be risks associated with organ inflammation due to an enhanced immune response.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been on a stable HIV treatment for 4 months, including a protease inhibitor or NNRTI.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Chiron CorporationLead Sponsor
24 Previous Clinical Trials
6,522 Total Patients Enrolled

Media Library

Anti-HIV Therapy Clinical Trial Eligibility Overview. Trial Name: NCT00002449 — Phase 1
Human Immunodeficiency Virus Infection Research Study Groups:
Human Immunodeficiency Virus Infection Clinical Trial 2023: Anti-HIV Therapy Highlights & Side Effects. Trial Name: NCT00002449 — Phase 1
Anti-HIV Therapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT00002449 — Phase 1
Human Immunodeficiency Virus Infection Patient Testimony for trial: Trial Name: NCT00002449 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research endeavor include enrollees over the age of seventy?

"This medical trial is searching for participants aged between 18 and 65. Additionally, there are 108 studies focused on minors and 352 trials interested in seniors over the age of 65."

Answered by AI

Has the Federal Drug Administration sanctioned this therapy?

"The safety of this treatment is estimated by our team at Power to be a 1, due to the fact that it belongs in Phase 1 trials with limited evidence for both efficacy and safety."

Answered by AI

Do I meet the prerequisites needed to join this medical research?

"In order to be eligible for this trial, prospective participants must have HIV and should fall between 18-65 years of age. This study is currently looking to recruit a total number of 212 individuals."

Answered by AI

Is there still an opportunity to participate in this experiment?

"Clinicaltrials.gov reveals that the initial posting for this study was on August 1st 1999, and it has not been updated since June 23rd 2005. Unfortunately, no new participants can join at this time; however, there are over four-hundred eighty other trials actively recruiting patients right now."

Answered by AI

In what locations is the experiment being conducted?

"This trial is currently accepting participants from a total of 23 sites, with three major hubs in Fountain Valley, Chicago and Albany. To reduce the burden of participating in this study, it is highly advisable to choose the medical centre closest to you."

Answered by AI

Who else is applying?

What state do they live in?
Alabama
New York
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
0
What site did they apply to?
Sorra Research Ctr / Med Forum

Why did patients apply to this trial?

To help with the research.
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy
1999. "Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00002449.
All > Hiv Infection
~8 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top